INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 223 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.86 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $72,095 | +538.0% | 185,334 | +632.3% | 0.00% | – |
Q2 2023 | $11,301 | -20.2% | 25,310 | +46.6% | 0.00% | – |
Q1 2023 | $14,158 | -41.1% | 17,266 | +12.0% | 0.00% | – |
Q4 2022 | $24,043 | -14.1% | 15,412 | -6.3% | 0.00% | – |
Q3 2022 | $28,000 | +154.5% | 16,441 | +162.7% | 0.00% | – |
Q2 2022 | $11,000 | -21.4% | 6,258 | +63.0% | 0.00% | – |
Q1 2022 | $14,000 | – | 3,840 | +5385.7% | 0.00% | – |
Q4 2021 | $0 | -100.0% | 70 | -90.4% | 0.00% | – |
Q3 2021 | $5,000 | +25.0% | 727 | +63.7% | 0.00% | – |
Q2 2021 | $4,000 | +300.0% | 444 | +255.2% | 0.00% | – |
Q1 2021 | $1,000 | -100.0% | 125 | -100.0% | 0.00% | – |
Q4 2020 | $2,434,000 | -72.8% | 275,048 | -64.3% | 0.00% | -100.0% |
Q3 2020 | $8,939,000 | +4604.7% | 770,600 | +10836.7% | 0.00% | – |
Q2 2020 | $190,000 | -91.4% | 7,046 | -98.2% | 0.00% | – |
Q3 2018 | $2,221,000 | – | 399,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Round Table Services, LLC | 129,500 | $1,207,000 | 0.72% |
STONERIDGE INVESTMENT PARTNERS LLC | 252,376 | $2,352,000 | 0.34% |
Bellevue Group AG | 155,000 | $1,445,000 | 0.26% |
WASATCH ADVISORS LP | 1,861,553 | $17,350,000 | 0.26% |
Blue Clay Capital Management, LLC | 13,000 | $121,000 | 0.14% |
Virtus ETF Advisers LLC | 24,058 | $224,000 | 0.11% |
EMERALD ADVISERS, LLC | 203,737 | $1,899,000 | 0.08% |
Vident Investment Advisory, LLC | 63,383 | $591,000 | 0.08% |
Thomas J. Herzfeld Advisors, Inc. | 15,000 | $140,000 | 0.08% |
GSA CAPITAL PARTNERS LLP | 94,400 | $880,000 | 0.05% |